What is Rukobia (fostemsavir) for?
Buy Rukobia (fostemsavir). Rukobia (fostemsavir) is a new drug for HIV-1 treatment. It works best with other HIV medicines. It’s for adults who have tried many treatments but still can’t control their HIV.
How does Rukobia (fostemsavir) work?
The main part of Rukobia is called fostemsavir. It’s a unique HIV-1 attachment inhibitor.
Attachment inhibitors block HIV’s gp120 from attaching to T cells. This stops HIV from entering and multiplying inside the body.
When you take Rukobia, it turns into temsavir in your body. Temsavir then blocks gp120, stopping HIV from infecting cells. This helps keep HIV from growing and spreading.
Where has Rukobia (fostemsavir) been approved?
Rukobia (fostemsavir) has been approved by:
- Food and Drug Administration (FDA), USA on July 2, 2020
This medicine might also be approved in other places. If you’re unsure, contact our support team.
How is Rukobia (fostemsavir) taken?
The usual dose is:
- One 600 mg tablet taken orally twice daily with or without food. Swallow tablets whole. Do not chew, crush, or split tablets.
For more details on dosage and how to take Rukobia, see the official prescribing information.
Always talk to your doctor about the right dose for you and any possible drug interactions.
Are there any known side effects or adverse reactions of Rukobia (fostemsavir)?
Common adverse reactions
The most common side effect is nausea.
Serious adverse reactions
Some serious side effects include:
- Immune reconstitution syndrome has been reported in patients treated with combination antiretroviral therapies.
- QTc prolongation: Use Rukobia with caution in patients with a history of QTc prolongation or with relevant pre-existing cardiac disease or who are taking drugs with a known risk of Torsade de Pointes.
- Elevations in hepatic transaminases in patients with hepatitis B or C virus co-infection: Elevations in hepatic transaminases were observed in a greater proportion of subjects with HBV and/or HCV co-infection compared with those with HIV mono-infection.
- Risk of Adverse Reactions or Loss of Virologic Response Due to Drug Interactions: The concomitant use of Rukobia and certain other drugs may result in known or potentially significant drug interactions, some of which may lead to: 1) Loss of therapeutic effect of Rukobia and possible development of resistance due to reduced exposure of temsavir; 2) Possible prolongation of QTc interval from increased exposure to temsavir.
Contraindications
Don’t take Rukobia if you’re allergic to fostemsavir or any part of the drug.
Also, avoid taking it with strong CYP3A inducers. This can lower temsavir levels and reduce its effectiveness.
Use in a specific population
Breastfeeding is not advised because it may spread HIV-1.
For a full list of side effects and adverse reactions, see the official prescribing information.